HTRA2 and cancer: Actually, an emerging chemotherapy-resistance mechanism, driven by WT1 downregulation, due to transcript cleavage via HTRA2, a protease overexpressed under cytotoxic therapy, has been shown to increase cancer cell survival, based on C-MYC/JUNB upregulation, which is normally repressed by WT1 [136].